198 related articles for article (PubMed ID: 14671316)
1. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
Barbie TU; Barbie DA; MacLaughlin DT; Maheswaran S; Donahoe PK
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15601-6. PubMed ID: 14671316
[TBL] [Abstract][Full Text] [Related]
2. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
3. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
4. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism.
Ha TU; Segev DL; Barbie D; Masiakos PT; Tran TT; Dombkowski D; Glander M; Clarke TR; Lorenzo HK; Donahoe PK; Maheswaran S
J Biol Chem; 2000 Nov; 275(47):37101-9. PubMed ID: 10958795
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
6. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
7. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
8. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
[TBL] [Abstract][Full Text] [Related]
9. Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.
Hwang SJ; Suh MJ; Yoon JH; Kim MR; Ryu KS; Nam SW; Donahoe PK; Maclaughlin DT; Kim JH
Int J Oncol; 2011 Oct; 39(4):811-20. PubMed ID: 21573503
[TBL] [Abstract][Full Text] [Related]
10. Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis.
Namkung J; Song JY; Jo HH; Kim MR; Lew YO; Donahoe PK; MacLaughlin DT; Kim JH
J Clin Endocrinol Metab; 2012 Sep; 97(9):3224-30. PubMed ID: 22761458
[TBL] [Abstract][Full Text] [Related]
11. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Segev DL; Hoshiya Y; Hoshiya M; Tran TT; Carey JL; Stephen AE; MacLaughlin DT; Donahoe PK; Maheswaran S
Proc Natl Acad Sci U S A; 2002 Jan; 99(1):239-44. PubMed ID: 11773638
[TBL] [Abstract][Full Text] [Related]
12. Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop.
Howard CM; Claudio PP; De Luca A; Stiegler P; Jori FP; Safdar NM; Caputi M; Khalili K; Giordano A
Cancer Res; 2000 May; 60(10):2737-44. PubMed ID: 10825149
[TBL] [Abstract][Full Text] [Related]
13. Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smad-independent mechanism.
Tran TT; Segev DL; Gupta V; Kawakubo H; Yeo G; Donahoe PK; Maheswaran S
Mol Endocrinol; 2006 Oct; 20(10):2382-91. PubMed ID: 16740653
[TBL] [Abstract][Full Text] [Related]
14. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.
Renaud EJ; MacLaughlin DT; Oliva E; Rueda BR; Donahoe PK
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):111-6. PubMed ID: 15618407
[TBL] [Abstract][Full Text] [Related]
15. Characterization of mullerian inhibiting substance binding on cervical carcinoma cells demonstrated by immunocytochemistry.
Wang JJ; Roffler SR; Chou HH; Yin FY; Yin CS
Tissue Cell; 1994 Jun; 26(3):467-76. PubMed ID: 8073421
[TBL] [Abstract][Full Text] [Related]
16. Antibody against avian müllerian inhibiting substance (MIS) recognizes MIS on rat müllerian duct and human tumor cells.
Wang JJ; Teng CS
Proc Natl Sci Counc Repub China B; 1989 Oct; 13(4):267-75. PubMed ID: 2484046
[TBL] [Abstract][Full Text] [Related]
17. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.
Fuller AF; Guy S; Budzik GP; Donahoe PK
J Clin Endocrinol Metab; 1982 May; 54(5):1051-5. PubMed ID: 6895900
[TBL] [Abstract][Full Text] [Related]
18. p107 and p130: versatile proteins with interesting pockets.
Classon M; Dyson N
Exp Cell Res; 2001 Mar; 264(1):135-47. PubMed ID: 11237530
[TBL] [Abstract][Full Text] [Related]
19. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
[TBL] [Abstract][Full Text] [Related]
20. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
